Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Details

Language :

English

ISSN :

10780998

Volume :

30

Issue :

12

Database :

Complementary Index

Journal :

Inflammatory Bowel Diseases

Publication Type :

Academic Journal

Accession number :

181987469

Full Text :

https://doi.org/10.1093/ibd/izae024